Neu­ro­science leg­end Steve Paul re­tires; Ex­clu­sive: GSK hires ex-In­nate Phar­ma CEO for new po­si­tion

If you’re in neu­ro­science, you’ve prob­a­bly heard of him.

Few peo­ple have dipped a hand in as many neu­ro­science biotechs and gov­ern­ment re­search units as Steve Paul, and he’s go­ing out (near­ly) on top.

The decades­long CNS drug dis­cov­ery and de­vel­op­ment vet­er­an re­tired from his post as chief sci­en­tif­ic of­fi­cer and pres­i­dent of R&D at Karuna Ther­a­peu­tics on Jan. 16, just weeks af­ter ink­ing a $14 bil­lion ex­it to Bris­tol My­ers Squibb.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.